Viada-González C, Lorenzo-Monteagudo G, Ramos-Suzarte M, Álvarez-Cardona M, Frías-Blanco ANeninger-Vinagera E, Rodríguez PC, Crombet-Ramos Tania

Language: Spanish
References: 19
Page: 69-80
PDF size: 636.18 Kb.

ABSTRACT

This report corresponds to quality of life analysis of patient with non-small cell lung cancer included in the phase III clinical trials Evaluation of CIMAvaxEGF® vaccine in lung cancer. The quality of life was evaluate using the EORTC questionnaires QLQ-C30 y QLQ-C13, at the beginning and every 3 months. To compare the median between two groups the Mann-Whitney non-parametric test was used. To compare the baseline and different follows times the Wilcoxon non-parametric test was used. The QLQ-C30 questionnaire showed a benefit in terms of the quality of life for the CIMAvaxEGF® vaccine group on the functional scores (global, role and social) and symptoms of the disease (pain). The QLQ-LC13 questionnaire showed a benefit in terms of the quality of life for the CIMAvaxEGF® vaccine group on the symptoms scores (dyspnea, dysphagia, alopecia and chest pain). It is noted as significant that the hemoptysis decreases in the group vaccinated as well as the dysphagia, the cough and the dyspnea observing a worsening in the control group.

REFERENCES

1. Cruz-Bermudez HF, Moreno-Collazos JE, Angarita-Fonseca A. Medición de la calidad de vida por el cuestionario QLQ-C30 en sujetos de diversos tipos de cáncer en la ciudad de Bucaramanga, Colombia. Enferm Glob. 2013;12(30):294-303. Disponible en: http://scielo.isciii.es/pdf/eg/v12n30/administracion5.pdf.]

2. Bottomley A, Aaronson NK, European Organisation for Research and Treatment of Cancer. International perspective on healthrelated quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol. 2007;25:5082-6.]

3. CECMED. Resumen de las características del producto CIMAvax-EGF(r). La Habana: Registro Cubano de Ensayos Clínicos; 2012. Disponible en: http://www.cecmed.cu/rcp-biologicos?page=9.]

4. García-Verdecia B. Estudio de la respuesta inmune humoral inducida con la vacuna CIMAvax-EGF y de su relación con la supervivencia de pacientes con cáncer de pulmón de células no pequeñas [Tesis de Doctorado]. La Habana: Universidad de La Habana; 2012. Disponible en: http://tesis.sld.cu/FileStorage/000162-1D00-BGarciaVerdecia.pdf.]

5. Ricardo-Sosa O, González-Portales Y, Ramos-Ferro M, Battles-Zamora S, Díaz-Hernandez P, Ortega-Peguero M, et al. Experiencia en enfermería, ensayo clínico y atención a pacientes con cáncer de pulmón. Rev Cubana Invest Bioméd. 2015;34(2):1-10. Disponible en: http://scielo.sld.cu/pdf/ibi/v34n2/ibi04215.pdf]

6. RodriguezRodríguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T et al. A Phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22(15):3782-90. doi: https://10.1158/1078-0432.CCR-15-0855.]

7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst.1993; 85: 365-76.]

8. EORTC Quality of Life. EORTC QLQ-C30 (versión 3) Quality of life of cancer patients questionnaire. Bruselas: EORTC Quality of Life. Disponible en: https://qol.eortc.org/questionnaire/eortc-qlq-c30/(Consultado en línea: 01 de enero 2021).]

9. Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, et al. On behalf of the EORTC Quality of Life Group, EORTC Lung Cancer Group, and European Society of Thoracic Surgeons. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol. 2017;28(11):2874-81. doi: https://10.1093/annonc/mdx453.]

10. Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 Reference Values Manual. Bruselas: EORTC Quality of Life Group;2008. Disponible en: https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf (Consultado en línea: 01 de enero 2021).]

11. Sáanchez L, Muchene L, Lorenzo-Luaces P, Viada C, Rodriguez PC, Alfonso S et al. Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. Semin Oncol. 2018;45(1-2):52-7. doi: https://10.1053/j.seminoncol.2018.04.005.]

12. Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A et al. CIMAvax-EGF: Toward long-term survival of advanced NSCLC. Semin Oncol. 2018;45(1-2):34-40. doi: https:// 10.1053/j.seminoncol.2018.04.009.]

13. Saavedra D, Crombet T. CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol. 2017;8:269. doi: https:// 10.3389/fimmu.2017.00269.]

14. Saavedra D, García B, Lorenzo-Luaces P, González A, Popa X, Fuentes KP, et al. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother. 2016;65(1):37-45. doi: https://10.1007/s00262-015-1773-6.]

15. Crombet-Ramos T, Rodríguez PC, Neninger-Vinageras E, Garcia-Verdecia B, Lage-Dávila A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(10):1303-11. doi: https://10.1586/14760584.2015.1079488.]

16. Fernández-Lorente A, Acosta-Brooks S, Neninger-Vinageras E, Barroso-Alvarez MC, Wilkinson-Brito B, Troche-Concepción M, et al. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax(r) EGF. World J Surg Oncol. 2013;11:275. doi: https://10.1186/1477-7819-11-275.]

17. Rodríguez PC, Neninger E, García B, Popa X, Viada C, Luaces P et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines. 2011;9:7. doi: https://10.1186/1476-8518-9-7.]

18. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010;12(1):17-23.]

19. Neninger E, García-Verdecia B, Crombet T, Viada C, Pereda S, Leonard I, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother. 2009;32(1):92-9. doi: https://10.1097/CJI.0b013e31818fe167https://10.1097/CJI.0b013e31818fe167.]